2049079-64-1
Chemical Structure
Sutimlimab
Synonym(s): BIVV009; IPN-009; TNT009
- CAS No.: 2049079-64-1
- Formula:N/A
- Molecular Weight:(144.8 kDa)
IUPAC Name: (33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-(methyl-13C-d3)cyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-15,16,17,18-d4-35-carboxamide
SMILES: [Sutimlimab]
Biological Activity: Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sutimlimab | 98.81% | Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Alexander Röth, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [Content Brief]
- [2]. Cole MA, et al. Complement Biosensors Identify a Classical Pathway Stimulus in Complement-Mediated Hemolytic Uremic Syndrome. bioRxiv [Preprint]. 2024 Jun 2:2024.05.29.596475. [Content Brief]
- [3]. Berentsen S. Sutimlimab for the Treatment of Cold Agglutinin Disease. Hemasphere. 2023 May 2;7(5):e879. [Content Brief]
